{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:43:56Z","timestamp":1791150236398,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Diazoxide has been used globally for hyperinsulinemic hypoglycemia. However, serious adverse drug reactions, such as pulmonary hypertension (PH), are major concerns. This study aimed to determine the baseline risk of diazoxide administration leading to the development of PH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted at a tertiary care institution in Tokyo, Japan. Children under 15 years old treated with diazoxide for congenital hyperinsulinemia between May 2015 and May 2024 were included. Data were extracted from electronic medical records. The primary endpoint was the development of PH, with cases that developed PH labeled as PH (+) and those that did not as PH (\u2013). Patient backgrounds, including chromosomal abnormalities, congenital heart disease, gestational age, and birth weight, were extracted as explanatory variables for PH development. We adjunctively applied the Bayesian estimation for PH after diazoxide administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 65 children (median age 14 days), 3 (5%) children were PH (+). Comparing PH (+) and PH (\u2013), trisomy 13 was identified as a significant risk factor (100% vs. 0%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The birth weight also differed significantly (1491 vs. 2056 g,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.049). There were no significant differences in gestational age or the presence of congenital heart disease. In the PH (+) group, the maximum doses of diazoxide ranged from 2.5 to 12 mg\/kg\/day, and all children received prophylactic diuretics. We estimated the posterior probability of PH complicated by diazoxide as 19% in the trisomy 13 group and 0.4% in the nontrisomy 13 group using the empirical Bayesian method.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Trisomy 13 significantly increased the risk of PH following diazoxide administration. Even low-dose diazoxide and prophylactic diuretics may not prevent PH in these patients. Caution is essential when prescribing diazoxide to children with trisomy 13 and low birth weight.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/apc.apc_65_25","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T13:00:09Z","timestamp":1767272409000},"page":"351-356","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Trisomy 13 as a risk factor for pulmonary hypertension induced by diazoxide"],"prefix":"10.4103","volume":"18","author":[{"given":"Kazu","family":"Ishikawa","sequence":"first","affiliation":[{"name":"Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan"},{"name":"Department of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiro","family":"Nakao","sequence":"additional","affiliation":[{"name":"Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan"},{"name":"Department of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shinjo","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics and Interdisciplinary Medicine, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"R1-20260420","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/siny.2001.0090","article-title":"Persistent hyperinsulinaemic hypoglycaemia","volume":"7","author":"de Lonlay","year":"2002","journal-title":"Semin Neonatol"},{"key":"R2-20260420","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev.me.30.020179.001525","article-title":"Diagnosis and medical management of insulinomas","volume":"30","author":"Fajans","year":"1979","journal-title":"Annu Rev Med"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41372-018-0218-4","article-title":"Prevalence and safety of diazoxide in the neonatal intensive care unit","volume":"38","author":"Gray","year":"2018","journal-title":"J Perinatol"},{"key":"R4-20260420","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1297\/cpe.27.131","article-title":"Safety and effectiveness, including intelligence prognosis, of diazoxide in pediatric patients with hyperinsulinemic hypoglycemia: Special survey in Japan (long-term, all-case survey)","volume":"27","author":"Fukutomi","year":"2018","journal-title":"Clin Pediatr Endocrinol"},{"key":"R5-20260420","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1210\/jc.2018-01613","article-title":"Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide","volume":"103","author":"Herrera","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000356772","article-title":"High prevalence of severe circulatory complications with diazoxide in premature infants","volume":"105","author":"Yoshida","year":"2014","journal-title":"Neonatology"},{"key":"R7-20260420","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.pedneo.2021.06.010","article-title":"Diazoxide toxicity with hypoglycemia in infants with trisomy 13","volume":"62","author":"Nagaoka","year":"2021","journal-title":"Pediatr Neonatol"},{"key":"R8-20260420","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000497458","article-title":"Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism","volume":"91","author":"Thornton","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"R9-20260420","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/cen.14987","article-title":"Low-dose diazoxide is safe and effective in infants with transient hyperinsulinism","volume":"100","author":"Malhotra","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R10-20260420","first-page":"5","article-title":"Diazoxide for neonatal hyperinsulinemic hypoglycemia and pulmonary hypertension","volume":"10","author":"Newman-Lindsay","year":"2022","journal-title":"Children (Basel)"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/01.CIR.27.5.895","article-title":"Hypotensive and renal effects of diazoxide, a sodiumretaining benzothiadiazine compound","volume":"27","author":"Bartorelli","year":"1963","journal-title":"Circulation"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00246-020-02444-6","article-title":"Cardiac surgery in trisomy 13 and 18: A guide to clinical decision-making","volume":"41","author":"Carvajal","year":"2020","journal-title":"Pediatr Cardiol"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/ajmg.a.34285","article-title":"The impact of cardiac surgery in patients with trisomy 18 and trisomy 13 in Japan","volume":"155A","author":"Maeda","year":"2011","journal-title":"Am J Med Genet A"},{"key":"R14-20260420","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajmg.a.36282","article-title":"Medial defects of the small pulmonary arteries in fatal pulmonary hypertension in infants with trisomy 13 and trisomy 18","volume":"164A","author":"Tahara","year":"2014","journal-title":"Am J Med Genet A"},{"key":"R15-20260420","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ajmg.a.30147","article-title":"Hyperinsulinemic hypoglycemia in a newborn infant with trisomy 13","volume":"129A","author":"Tamame","year":"2004","journal-title":"Am J Med Genet A"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"894","DOI":"10.5301\/jn.5000220","article-title":"Relationships between glomerular filtration rate and kidney volume in low-birth-weight neonates","volume":"26","author":"Kandasamy","year":"2013","journal-title":"J Nephrol"},{"key":"R17-20260420","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajmg.a.34423","article-title":"Anthropometric charts for infants with trisomies 21, 18, or 13 born between 22 weeks gestation and term: The VON charts","volume":"158A","author":"Boghossian","year":"2012","journal-title":"Am J Med Genet A"},{"key":"R18-20260420","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/ajmg.a.62133","article-title":"Surveillance guidelines for children with trisomy 13","volume":"185","author":"Kepple","year":"2021","journal-title":"Am J Med Genet A"},{"key":"R19-20260420","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bmj.2.5298.159","article-title":"Antihypertensive action of diazoxide. A new benzothiazine with antidiuretic properties","volume":"2","author":"Hutcheon","year":"1962","journal-title":"Br Med J"},{"key":"R20-20260420","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1536\/ihj.20-024","article-title":"Pulmonary hypertension following increased dosing of diazoxide in an infant","volume":"61","author":"Ohnishi","year":"2020","journal-title":"Int Heart J"}],"container-title":["Annals of Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/apc.apc_65_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:58:11Z","timestamp":1786647491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/apc.apc_65_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/apc.apc_65_25","relation":{},"ISSN":["0974-2069","0974-5149"],"issn-type":[{"value":"0974-2069","type":"print"},{"value":"0974-5149","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-03-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}